Tokuoka Kentaro, Takayanagi Risa, Toyabe Mioko, Watanabe Masayuki, Kitagawa Yasuhisa, Yamada Yasuhiko
Department of Neurology, Tokai University Hachioji Hospital, 1838 Ishikawa-cho, Hachioji, Tokyo, 192-0032, Japan,
J Headache Pain. 2015;16:71. doi: 10.1186/s10194-015-0558-9. Epub 2015 Aug 5.
In this study, we retrospectively analyzed the relationship between headache recurrence and serotonin 5-HT1B/1D receptor occupancy (Φ1B and Φ1D). Triptans marketed in Japan (sumatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan) were investigated.
Receptor occupancies were calculated from both the pharmacokinetic and pharmacodynamic data of triptans. We examined the relationships between recurrence rate and elimination half-lives, and Ф1B and Ф1D, as calculated from the time-course of plasma drug concentration obtained from other studies. The time until Ф1B and Ф1D became 50% or less, 40% or less, and 30% or less was calculated as duration time to examine the relationship with recurrence rate.
For Ф1B, eletriptan remained at a low level. For Ф1D, it was indicated that all triptans obtained an occupancy of 80% or higher at maximum. For all items, though recurrence tended to be lower along with longer half-life, no significant statistical correlation was found. For both Ф1B and Ф1D, the recurrence rate tended to be lower as the duration became longer. In addition, a significant correlation was observed for Ф1D (p < 0.05). For clarifying the Ф value and time period most closely correlated with recurrence rate, recurrence and Ф1B and Ф1D at 6, 12, and 18 h after administration were calculated. The most significant correlation was observed between recurrence rate and Ф1D at 12 h after administration (p < 0.01).
As an index for evaluating headache recurrence following triptan administration, recurrence rate and Ф1D value at 12 h after administration were found to be most closely correlated and useful for analysis. Our results indicate that headache recurrence inhibition can be evaluated using these values.
在本研究中,我们回顾性分析了头痛复发与5-羟色胺5-HT1B/1D受体占有率(Φ1B和Φ1D)之间的关系。对在日本上市的曲坦类药物(舒马曲坦、佐米曲坦、依立曲坦、利扎曲坦、那拉曲坦)进行了研究。
根据曲坦类药物的药代动力学和药效学数据计算受体占有率。我们研究了复发率与消除半衰期以及根据其他研究获得的血浆药物浓度时间过程计算得出的Φ1B和Φ1D之间的关系。将Φ1B和Φ1D降至50%或更低、40%或更低以及30%或更低所需的时间计算为持续时间,以研究其与复发率的关系。
对于Φ1B,依立曲坦维持在较低水平。对于Φ1D,结果表明所有曲坦类药物的最大占有率均达到80%或更高。对于所有项目,虽然复发率往往随着半衰期延长而降低,但未发现显著的统计学相关性。对于Φ1B和Φ1D,随着持续时间延长,复发率均有降低趋势。此外,观察到Φ1D存在显著相关性(p < 0.05)。为了明确与复发率最密切相关的Φ值和时间段,计算了给药后6、12和18小时的复发率以及Φ1B和Φ1D。给药后12小时的复发率与Φ1D之间观察到最显著的相关性(p < 0.01)。
作为评估曲坦类药物给药后头痛复发的指标,发现给药后12小时的复发率与Φ1D值最密切相关且对分析有用。我们的结果表明,可使用这些值评估头痛复发抑制情况。